#ESMO20 Wonderful discussion of the VEGF/EGFR oral presentations given by @LeciaSequist framing the results in the current landscape. #LCSM @OncoAlert
#ESMO20 Targeting angiogenesis in NSCLC is an effective strategy, with several regimens approved including in patients with #EGFR mutant NSCLC, reflected in @NCCN guidelines though conspicuously absent is gefitinib + chemotherapy, which offered an OS benefit over TKI alone. #LCSM
#ESMO20 There's a history between EGFR and VEGF. The pattern: improved PFS but not OS. Do we need OS? Definitely if QoL is impacted.
#ESMO20 For ACTIVE, with apatinib + gefitinib, tolerability was suboptimal. Grade 3 diarrhea rates were quite high which will impact its clinical utility. #LCSM @OncoAlert
#ESMO20 Where does apatinib sit in comparison to other trials? Helpful summary here by @LeciaSequist for posterity. #LCSM @OncoAlert
#ESMO20 Overall, some signal with targeting VEGF in #EGFR mutant NSCLC but unclear impact on survival. Waiting for more phase III studies featuring osimertinib but may need a biomarker to help guide optimal use. #LCSM @OncoAlert
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.